SEARCH RESULTS FOR:
Dr. Seyfullah Dağıstanlı & Aytek Dağıstanlı
FOUNDER & BUSINESS DEVELOPMENT MANAGER, DELTAPV
DeltaPV is Turkey’s leading provider of pharmacovigilance in Turkey and exports its services abroad.
Peter Meath
MANAGING DIRECTOR & CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, J.P. MORGAN COMMERCIAL BANKING
.P.Morgan explains the complete ecosystem that it has developed for life science companies, aiming to serve their needs throughout their entire life cycle, from opening a bank account on Day 1, to expanding internationally and through a potential IPO and beyond.
Heine Melkevik
MANAGING DIRECTOR, EQUINOR NIGERIA
Equinor, the world’s largest offshore operator, explains from Nigeria the struggles of regulatory uncertainty and analyses its local content.
Paul Murphy
MANAGER – SOUTH AMERICA, MINING PLUS
Mining Plus explains the trends that are effecting its business in Peru and South America more generally.
Jamie Levy
PRESIDENT & CEO, GENERATION MINING
Generation Mining explains the developments at its flagship Marathon PGM project in Northern Ontario.
Enoch Kusi-Yeboah
GENERAL MANAGER, METSO MINERALS GHANA
From its offices in Ghana, Metso comments on how its offering is developing alongside the West African mining industry.
Enrique Garay
SENIOR VICE PRESIDENT, RIO2 LIMITED
The team from Rio Alto attempt to replicate its success with Rio2, beginning with Rio2’s Fenix Gold project.
Mark Venning
REGIONAL MINING LEADER, SOUTH AMERICA, STANTEC
Stantec comments on the current situation facing the EPCM market in Chile.
Ferhat Farsi
CEO AND CO-FOUNDER, CINNAGEN
CinnaGen Co. was founded in 1994 with the goal of manufacturing hi-tech products in biotechnology and related fields.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
